Insulin aspart biosimilar(Biocon Ltd.)

10+ Emerging Markets, Japan & ANZ Transition in Final Phase DUBAI, UAE, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. Continue Reading PFA the banner image (PRNewsfoto/Biocon Biologics Ltd) All Viatris' biosimilars brands, including Ogivri® & Hertraz® (bTrastuzumab), Abevmy® (bBevacizumab), Fulphila® (bPegfilgrastim), Hulio® (bAdalimumab), Nepexto® (bEtanercept), Semglee® (bGlargine) and Kirsty® (bAspart) are now part of Biocon Biologics' commercial franchise in Advanced Markets and 80+ Emerging Markets. Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities in India and Malaysia. Biocon Biologics will now have a strong commercial footprint across ~120 countries with a direct presence in the U.S., Canada, Europe and 9 key Emerging Market countries of India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines. "I am very proud and excited that we have successfully completed the integration of the acquired business across 120 countries. The conclusion of this final wave of transition is a significant milestone and marks the beginning of Biocon Biologics' transformation to a fully integrated global company. I congratulate and thank the entire Biocon Biologics team – colleagues, advisors, and partners. This seamless transition, achieved ahead of schedule, is an outcome of relentless focus, untiring efforts and an unwavering commitment to patients and business continuity." - Shreehas Tambe, CEO & Managing Director. "This milestone presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets. This self-led business model will take us closer to the patients, MoHs, prescribers and payers. It will allow us to expand affordable access to larger patient pools and generate significant savings for healthcare systems in these emerging markets, thus enabling equitable access to high quality biosimilars." - Susheel Umesh, Chief Commercial Officer - Emerging Markets. Biocon Biologics has made several key leadership appointments, built new capabilities and infrastructure from the ground up and set up dedicated teams to address the growing needs of patients and customers through self-led and partner or distributor-led commercial models to ensure business continuity for patients, prescribers, partners, and healthcare systems. Website: ; Twitter: @BioconBiologics; LinkedIn: Biocon Biologics SOURCE Biocon Biologics Ltd

Phalguni Deswal @Phalguni_GD The availability of biosimilars can help reduce the cost of insulin therapies. Image Credit: Daniel Beckemeier / Shutterstock. Meitheal Pharmaceuticals has signed an exclusive licensing agreement with the China-based Tonghua Dongbao Pharmaceutical to commercialise three insulin biosimilars in the US. The insulin biosimilars include two rapid-acting insulins, namely insulin lispro and insulin aspart, and the long-acting insulin glargine. The rights were acquired by Meitheal’s parent company Nanjing King-Friend Biochemical Pharmaceutical. Recommended Reports Reports LOA and PTSR Model - Injectable Hdv Basal Insulin For Type 1 And Type 2 Diabetes in Type 2 Diabetes GlobalData Reports LOA and PTSR Model - (Insulin Glargine + Insulin Lispro) La in Type 2 Diabetes GlobalData View all Companies Intelligence Sanofi Bristol-Myers Squibb Co Novo Nordisk AS Biocon Ltd Nanjing King-friend Biochemical Pharmaceutical Co Ltd View all Eli Lilly reported global sales of $440.4m for the branded version of insulin lispro Humalog in n Q2 2023, while Sanofi ’s Lantus (insulin glargine) had global sales of $353m in the same period, as per the company’s Q2 financials. Meitheal will have exclusive US marketing rights after the insulin biosimilars are approved by the US Food and Drug Administration (FDA), which is expected in 2026. As part of the agreement, both Tonghua Dongbao and Nanjing King-Friend Biochemical would be responsible for the development and supply of all three insulin biosimilars. All three companies will also share the royalties from the US sales. Although insulin suppliers such as Novo Nordisk , Eli Lilly, and Sanofi have reduced insulin prices in recent years , the cost of insulin remains quite high in the US. The list price for a 5-pack of Humalog 15mL is $530.40, as per Eli Lilly . The availability of biosimilars can help reduce the cost of insulin therapies, as has been seen in other therapy areas. Currently available insulin biosimilars include, Biocon and Viatris’ Semglee—a Lantus biosimilar—which  was the first insulin biosimilar approved by the FDA in 2021. Biocon also has a Novolog (insulin aspart) biosimilar, Kixelle , in its product catalogue. Kixelle has been approved in Europe. Meitheal has a number of generic drugs as part of its marketed portfolio, including several cancer drugs such as azacitidine, a generic of Bristol Myers Squibb’s Vidaza. Although Vidaza was first indicated for treatment of myelodysplastic syndromes (MDS) it is currently under investigation for treating relapsed acute myeloid leukaemia (AML) and anaplastic large cell lymphoma (ALCL).